ERBB2 and neoplasm: Based on the nomogram, points were signed for each variable, and a cumulative point could be calculated based on the patient’s pretreatment or preoperative inflammatory indexes (NLR and SII), tumor biomarkers (CEA and CA15-3), pathological results (HR status) and preoperative regimen (anti-HER2 therapy), in which lower scores were associated with a lower possibility of ISLN pCR (Figure 2).